Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Non-Current Assets (2022 - 2026)

Kura Oncology has reported Non-Current Assets over the past 5 years, most recently at $28.8 million for Q1 2026.

  • Quarterly Non-Current Assets rose 47.04% to $28.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $109.5 million through Mar 2026, up 66.24% year-over-year, with the annual reading at $29.7 million for FY2025, 93.74% up from the prior year.
  • Non-Current Assets was $28.8 million for Q1 2026 at Kura Oncology, down from $29.7 million in the prior quarter.
  • Over five years, Non-Current Assets peaked at $29.7 million in Q4 2025 and troughed at $9.1 million in Q2 2023.
  • The 5-year median for Non-Current Assets is $15.9 million (2024), against an average of $17.9 million.
  • Year-over-year, Non-Current Assets fell 6.83% in 2024 and then soared 93.74% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $9.9 million in 2022, then soared by 66.54% to $16.5 million in 2023, then decreased by 6.83% to $15.3 million in 2024, then soared by 93.74% to $29.7 million in 2025, then dropped by 3.13% to $28.8 million in 2026.
  • Per Business Quant, the three most recent readings for KURA's Non-Current Assets are $28.8 million (Q1 2026), $29.7 million (Q4 2025), and $28.7 million (Q3 2025).